KR20050084250A - 알츠하이머병의 예방 및 치료 - Google Patents

알츠하이머병의 예방 및 치료 Download PDF

Info

Publication number
KR20050084250A
KR20050084250A KR1020057010595A KR20057010595A KR20050084250A KR 20050084250 A KR20050084250 A KR 20050084250A KR 1020057010595 A KR1020057010595 A KR 1020057010595A KR 20057010595 A KR20057010595 A KR 20057010595A KR 20050084250 A KR20050084250 A KR 20050084250A
Authority
KR
South Korea
Prior art keywords
alkyl
bile acid
disease
inhibitors
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057010595A
Other languages
English (en)
Korean (ko)
Inventor
띠에리 깡똥
로렝 프라디에
헤수스 베나비데스
휴베르트 호이에르
한스-루드빅 쉐페르
Original Assignee
아방티 파르마 소시에테 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아방티 파르마 소시에테 아노님 filed Critical 아방티 파르마 소시에테 아노님
Publication of KR20050084250A publication Critical patent/KR20050084250A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
KR1020057010595A 2002-12-12 2003-12-10 알츠하이머병의 예방 및 치료 Withdrawn KR20050084250A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (fr) 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
FR0215722 2002-12-12

Publications (1)

Publication Number Publication Date
KR20050084250A true KR20050084250A (ko) 2005-08-26

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057010595A Withdrawn KR20050084250A (ko) 2002-12-12 2003-12-10 알츠하이머병의 예방 및 치료

Country Status (22)

Country Link
EP (1) EP1572174A1 (https=)
JP (1) JP2006514063A (https=)
KR (1) KR20050084250A (https=)
CN (1) CN1726016A (https=)
AR (1) AR042354A1 (https=)
AU (1) AU2003296802A1 (https=)
BR (1) BR0317280A (https=)
CA (1) CA2507945A1 (https=)
CO (1) CO5700712A2 (https=)
FR (1) FR2848452B1 (https=)
HR (1) HRP20050534A2 (https=)
MA (1) MA27500A1 (https=)
MX (1) MXPA05005556A (https=)
NO (1) NO20053341L (https=)
NZ (1) NZ540496A (https=)
PE (1) PE20040770A1 (https=)
PL (1) PL377110A1 (https=)
RS (1) RS20050420A (https=)
RU (1) RU2005121909A (https=)
TW (1) TW200503707A (https=)
WO (1) WO2004062652A1 (https=)
ZA (1) ZA200504656B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
CA2554809C (en) 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
JP2008518955A (ja) 2004-11-02 2008-06-05 ノースウェスタン ユニバーシティ ピリダジン化合物および方法
US8158627B2 (en) 2006-04-28 2012-04-17 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
KR101441725B1 (ko) * 2007-05-22 2014-09-18 오츠카 세이야쿠 가부시키가이샤 알츠하이머병 치료를 위한 카르보스티릴 유도체 및 도네페질을 포함하는 치료제
US20130108573A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
AU2012328526B2 (en) * 2011-10-28 2017-05-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
EP0572560B1 (en) * 1991-02-22 2003-01-29 SHAPIRO, Howard, K. Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
CA2258744A1 (en) * 1996-06-27 1997-12-31 G.D. Searle And Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
ATE320803T1 (de) * 1998-01-28 2006-04-15 Warner Lambert Co Verfahren zur behandlung von alzheimerschen krankheit
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
AU2001233299A1 (en) * 2000-02-04 2001-08-14 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
MXPA05005556A (es) 2005-07-26
BR0317280A (pt) 2005-11-08
PL377110A1 (pl) 2006-01-23
PE20040770A1 (es) 2004-12-10
FR2848452B1 (fr) 2007-04-06
CN1726016A (zh) 2006-01-25
FR2848452A1 (fr) 2004-06-18
WO2004062652A1 (fr) 2004-07-29
EP1572174A1 (fr) 2005-09-14
RU2005121909A (ru) 2006-01-20
RS20050420A (sr) 2007-04-10
ZA200504656B (en) 2006-08-30
JP2006514063A (ja) 2006-04-27
AR042354A1 (es) 2005-06-15
MA27500A1 (fr) 2005-08-01
AU2003296802A1 (en) 2004-08-10
CO5700712A2 (es) 2006-11-30
HRP20050534A2 (en) 2006-11-30
NO20053341D0 (no) 2005-07-08
NO20053341L (no) 2005-09-07
NZ540496A (en) 2008-04-30
TW200503707A (en) 2005-02-01
CA2507945A1 (fr) 2004-07-29

Similar Documents

Publication Publication Date Title
EP1014996B1 (en) Saccharide-containing compositions for treating alzheimer's disease and other amyloidoses
JP5816171B2 (ja) 神経変性障害における脳の健康を保護するための化合物、組成物および方法
JP5302900B2 (ja) 脂肪性肝疾患の治療用医薬組成物
US20260102392A1 (en) Prophylactic or therapeutic drug for neurodegenerative diseases
KR20050084250A (ko) 알츠하이머병의 예방 및 치료
CN1145482C (zh) 泛喹酮在治疗阿尔茨海默氏病中的用途
KR20260011783A (ko) 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 비알코올성 지방간 질환 예방 또는 치료용 약학적 조성물
US20040138145A1 (en) Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease
US20240390377A1 (en) Composition for the prevention or treatment of neurodegenerative or motor neuron diseases comprising halofuginone as an active ingredient
US20120010264A1 (en) Novel medicament for treating cognitive impairment
US20020119934A1 (en) Methods for using specific saccharides for treating Alzheimer's disease and other amyloidoses
HK1083453A (en) Prevention and treatment of alzheimer's disease
CN107205973A (zh) 用于预防或治疗神经变性疾病的含有Ramalin的组合物
HK40060507B (zh) 包含环（组氨酸-脯氨酸）二肽及甲状旁腺激素的组合物用於预防、改善或治疗骨质流失疾病的用途
HK1165792A (en) Novel therapeutic agent for cognitive impairment

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050610

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid